News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TSLA
SPY
FB
Is this where the Gay Bar used to be?
God this board sucks donkey Balls!
UA short
KRE Regional Banks ETF 27.41
http://finance.yahoo.com/q/op?s=KRE&m=2012-01
Goldman Sachs Raises Estimates and Price Targets for Regional Banks (KEY, STI, FITB, CMA, more...)
http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Raises+Estimates+an+Price+Targets+for+Regional+Banks+(KEY,+STI,+FITB,+CMA,+more...)/5509618.html
FDA BIOD Oct 30, 2010
Biodel (BIOD)
Drug/indication: VIAject for diabetes
Approval decision date: Oct. 30
VIAject is a fast-acting insulin analogue designed for absorption into the bloodstream that's faster than currently marketed rapid-acting insulins.
FDA VVUS July 13 & Oct 28, 2010
Vivus (VVUS)
Drug/indication: Qnexa for obesity
Approval decision date: October 28
The FDA has scheduled an advisory committee meeting on July 15 to review Qnexa's safety and efficacy as a weight-loss drug. The FDA's review of Qnexa will be posted to the agency's web site on July 13 or July 14.
FDA JAZZ Oct 11, 2010
Jazz Pharmaceuticals (JAZZ)
Drug/indication: JZP-6 for fibromyalgia
Approval decision date: Oct. 11
JZP-6 contains the same active ingredient as Xyrem, which Jazz currently markets in the U.S. as a treatment for excessive daytime sleepiness and cataplexy in adult patients with narcolepsy.
FDA ALXA Oct 11, 2010
Alexza Pharmaceuticals (ALXA)
Drug/indication: AZ-004 for agitation in patients with schizophrenia or bipolar disorder
Approval decision date: Oct. 11
AZ-004 is an inhaled formulation of the generic antispsychotic drug loxapine, intended for the rapid treatment of adults with schizophrenia or bipolar disorder. Biovail(BVF) will market AZ-004 in the U.S. and Canada, if approved.
FDA SVNT Sept 14 2010
Savient Pharmaceuticals (SVNT)
Drug/indication: Krystexxa for gout
Approval decision date: Sept. 14
The FDA refused to approve Krystexxa last August, citing problems with the way the drug is manufactured. Savient revised the Krystexxa manufacturing process and submitted a response in March to the FDA's complete response letter.
FDA NVS June 2010--Gilenia for multiple sclerosis
July $60 .05/.15 with 9693 open interest (largest)
Novartis (NVS)
Drug/indication: Gilenia for multiple sclerosis
Approval decision date: June 2010 (Novartis has not disclosed the exact date.)
The FDA is holding an advisory committee meeting on June 10 to review Gilenia. If approved, Gilenia would be the first multiple sclerosis drug administered as a pill, and as such, the drug could have an impact on already approved, injectable MS drugs from Biogen Idec(BIIB), Teva(TEVA) and Merck-Serono.
FDA QCOR May 4 & June 11, 2010--
from 14 Bio....
May 21 $10 .25/.35
Questcor Pharmaceuticals (QCOR)
Drug/indication: Acthar for infantile spasms
Approval decision date: June 11
Prior to the FDA's approval decision date, an FDA advisory panel will review the safety and efficacy of Acthar on May 6. The FDA's review of Acthar is expected to post to the agency's web site on May 4 or May 5.
chart]www.stockscores.com/chart.asp?TickerSymbol=arnh&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
chart]stockcharts.com/c-sc/sc?s=GRPN&p=D&yr=0&mn=6&dy=0&i=p32508174489&r=5039[/chart]
chart]www.stockscores.com/chart.asp?TickerSymbol=aaph&TimeRange=30&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
placeholder
Wesley F. Whiting
LFUI Whiting
ASPE Whiting
enforcement@sec.gov
SPDR info: https://www.spdrs.com/product/fund.seam?ticker=XES
SDS - ProShares UltraShort S&P500
SSO - ProShares Ultra S&P500
SPY- S&P
FAZ -bear financials
URE - REIT http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49581812
UUP -$ Dollar cool town: http://www.carolinabeachtoday.com/
FDA lead: http://finance.yahoo.com/news/Arthritis-Drug-Vimovo-twst-3473823072.html?x=0&.v=1
Interesting relationship between Careclix, Docsconnect and PM Global Holdings. Also, the some of the same people are involved with VirtualVets as noted in my prior post.
It looks like Docsconnect has a strong relationship with Careclix and Dr. Korangy.
https://www.docsconnect.com
https://www.docsconnect.com/about-us/
And the many of the leadership at Docsconnect, including Dr. Korangy, are also with PM Global Holdings.
https://pmglobalholdings.com/leadership
I also noticed that Docsconnect was voluntarily dissolved on 01/15/2019 by Chairman Mathews
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=DOCSCONNECT%20L140001341810&aggregateId=flal-l14000134181-2fcb2008-65db-4377-b61c-40e387a179aa&searchTerm=docsconnct&listNameOrder=DOCSCONNECT%20L140001341810
But Ms. Mathews formed Docsconnectglobal on 05/08/2018
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=DOCSCONNECTGLOBAL%20L180001184320&aggregateId=flal-l18000118432-d98f24a7-d8a5-4a63-a9cc-54db4d3dfe2f&searchTerm=docsconnct&listNameOrder=DOCSCONNECT%20L140001341810
And just to confirm, I did call Docsconnect to confirm they are in operation which they are.
